Loading...
NPI 1861767147 · Baton Rouge, LA · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Adam Janot is a retina specialist (ophthalmology) physician provider located in Baton Rouge, Louisiana. This profile covers 19 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Adam Janot |
| Address | 7698 Goodwood Blvd |
| City | Baton Rouge |
| State | LA |
| ZIP | 70806 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | March 20, 2012 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.6M |
| Medicaid | $47.4K |
This provider’s revenue is heavily Medicare-weighted: lifetime Medicare revenue is $1.6M versus Medicaid revenue of $47.4K, so Medicare accounts for the overwhelming share of billed services and payments. The imbalance means payer-focused strategy and reimbursement risk are primarily tied to Medicare policy and utilization patterns rather than Medicaid.
Medicare revenue is highly concentrated in a few services: the precomputed top three Medicare codes account for 69.5% of the provider’s Medicare revenue, driven by J2777 (46.4%), Q5124 (12.6%), and 92012 (10.5%). Those codes indicate a practice model centered on intravitreal biologic therapy and ongoing office-based ophthalmic management rather than a broad mix of unrelated specialties.
Clinical/service-line mix from the Medicare top codes points to retina-focused, injection-driven care: J2777 (faricimab) is the single largest Medicare revenue source at $732.5K (46.4% of Medicare revenue), while Q5124 (biosimilar ranibizumab) and J0178 (aflibercept) show additional anti-VEGF activity. High-volume imaging and follow-up visits (92012, 92134) alongside these drug codes are consistent with chronic retinal disease management models such as wet AMD or diabetic macular edema.
Despite the injection-heavy revenue, competitive standing by national benchmarks is mixed. J2777 volume is typical for peers (rank #380 of 2039; 81th percentile), and Q5124 is also at a typical level nationally (rank #27 of 122; 79th percentile), but exam and imaging codes are extreme outliers: 92012 ranks #17 of 17177 (100th percentile) and 92134 ranks #298 of 26868 (99th percentile), indicating exceptionally high exam and retinal imaging volumes compared to national peers.
Medicaid revenue is extremely concentrated in office visits and imaging: the precomputed top three Medicaid codes account for 92.7% of the provider’s Medicaid revenue, with 92012 alone representing 61.0% of Medicaid revenue. This pattern shows Medicaid work is primarily routine established-patient management and retinal imaging rather than drug-infused procedures that drive Medicare revenue.
Within the state Medicaid competitive landscape the provider is a modest participant: 92012 is ranked #96 of 261 in-state (63th percentile) and 92134 is #64 of 133 (52th percentile), while 92014 is low in-state (rank #533 of 655; 19th percentile). Those ranks suggest the provider is neither dominant nor absent in the Louisiana Medicaid retina/ophthalmology market—Medicaid volumes are present but not leading.
Service mix includes some surgical retina work, but at more modest volumes compared with injections and imaging: procedure codes such as 67028 and 67042 appear on the Medicare list at typical national volumes (67028 rank #893 of 4255; 79th percentile and 67042 rank #176 of 1087; 83th percentile), indicating availability of surgical interventions but not a surgery-dominant practice model.
The provider has an established practice tenure (NPI enumerated 2012-03-20, ~14 years ago), which combined with very high volumes of follow-up exams and retinal imaging and concentrated injection revenue suggests a stable, retina-focused clinic that relies on recurring visits and biologic therapies; this concentration implies sensitivity to changes in biologic utilization, reimbursement rates, or coding for the top drug and exam codes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
19 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 25,260 | $30 | $732.5K |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 1,230 | $160 | $199.7K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 2,970 | $60 | $166.3K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,410 | $80 | $112.4K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 3,270 | $30 | $91.6K |
| J0178 | Injection, aflibercept, 1 mg | 130 | $560 | $75.4K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 390 | $120 | $45.3K |
| 67042 | In this procedure, the provider removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical cutting tool. He removes the internal limiting membrane of the retina… | 40 | $860 | $32.8K |
| J9035 | Injection, bevacizumab, 10 mg | 570 | $50 | $30.6K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 370 | $80 | $29.7K |
Showing 1–10 of 19
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 19 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
19 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 43 | 50 | 300 | $680 | $371.5K |
| J2777 | 3 | 30 | 6,660 | $30 | $309.4K |
| Q5124 | 1 | 10 | 760 | $160 | $123.1K |
| 67028 | 6 | 70 | 410 | $80 | $44.3K |
| 67042 | 3 | 20 | 20 | $1,110 | $26.6K |
| 92014 | 125 | 470 | 170 | $80 | $23.9K |
| 67036 | 8 | 10 | 20 | $950 | $23.7K |
| 67108 | 3 | 10 | 20 | $1,100 | $22K |
| 67113 | 2 | 10 | 20 | $1,180 | $18.8K |
| 92012 | 1 | 350 | 100 | $60 | $11.7K |
Showing 1–10 of 19
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 670 | $40 | $28.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 510 | $20 | $9.8K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 80 | $60 | $5.2K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 50 | $70 | $3.4K |
How this provider's Medicaid billing volume and revenue compare to other Louisiana providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Louisiana median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 533 | 660 | 1,070 | $60 | $129.3K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 825 | 1,170 | 160 | $80 | $102.7K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 96 | 260 | 330 | $30 | $41.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 64 | 130 | 490 | $10 | $19.4K |
Other providers in the same ZIP code as Adam Janot, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.